Cognetivity Neurosciences (STU:1UB) Selling, General, & Admin. Expense: €2.91 Mil (TTM As of Oct. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cognetivity Neurosciences Selling, General, & Admin. Expense?

Cognetivity Neurosciences STU:1UB Selling, General, & Admin. Expense is €2.91 Mil as of Oct. 2023.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Cognetivity Neurosciences's selling, general, & admin. expense for the three months ended in Oct. 2023 was €0.60 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Oct. 2023 was €2.91 Mil.


Cognetivity Neurosciences  (STU:1UB) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Cognetivity Neurosciences Selling, General, & Admin. Expense Related Terms


Cognetivity Neurosciences Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Cognetivity Neurosciences's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognetivity Neurosciences Selling, General, & Admin. Expense Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 2.19 1.38 1.50 8.73 3.88

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 1.12 0.65 0.55 0.60

STU:1UB vs VEEV, GEHC, HQY: Selling, General, & Admin. Expense Comparison

For the Health Information Services subindustry, Cognetivity Neurosciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences Selling, General, & Admin. Expense vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Selling, General, & Admin. Expense falls into.



Cognetivity Neurosciences Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €2.91 Mil mean?
Cognetivity Neurosciences (STU:1UB) has a Selling, General, & Admin. Expense of €2.91 Mil as of Oct. 2023. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Cognetivity Neurosciences and its competitors.
Is Cognetivity Neurosciences' Selling, General, & Admin. Expense too high?
Cognetivity Neurosciences' current Selling, General, & Admin. Expense is €2.91 Mil.
How does Cognetivity Neurosciences' Selling, General, & Admin. Expense compare to VEEV and GEHC?
Cognetivity Neurosciences' Selling, General, & Admin. Expense of €2.91 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Healthcare Providers & Services company?
A good Selling, General, & Admin. Expense depends on the Healthcare Providers & Services industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Cognetivity Neurosciences and its competitors. Cognetivity Neurosciences's current Selling, General, & Admin. Expense is €2.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (STU:1UB) has a current Selling, General, & Admin. Expense of €2.91 Mil. The current Selling, General, & Admin. Expense is €2.91 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Cognetivity Neurosciences (STU:1UB), the current Selling, General, & Admin. Expense is €2.91 Mil as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cognetivity Neurosciences Business Description

Address 800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.